203 indexable Biopharma Outsourcing companies headquartered in Canada, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $306.3M across 22 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
LSL Pharma Group
Integrated pharmaceutical company provides pharma products |
$12.6M | — | Public | Post IPO Sep 2025 | — | 2023 | ↑ Active |
| 2 |
Andira
Digital pharmacotherapeutic platform for providers |
$1.4M | — | Seed | Seed Feb 2026 | — | 2020 | ↑ Active |
| 3 |
Sirona Biochem
Developer of therapeutics for the treatment of skincare |
$7.4M | — | Public | Post IPO Apr 2025 | 11 | 2006 | ↑ Active |
| 4 |
ImmunoPrecise Antibodies
CDMO focused on antibody discovery and pre-clinical services |
$18.4M | — | Public | Post IPO Jul 2024 | 80 | 1989 | ↑ Active |
| 5 |
Voyageur Pharmaceuticals
Manufacturer of barium and iodine generic radiographic drugs |
$3.9M | — | Public | Grant (prize money) Feb 2025 | — | 2013 | ↑ Active |
| 6 |
AtomVie
Provider of diversified CDMO services for radiotherapeutics |
$90M | — | Series A | Series A Jun 2023 | 92 | 2021 | — |
| 7 |
adMare BioInnovations
Provider of biopharma consulting services |
$92M | — | Funding Raised | Grant (prize money) Mar 2022 | 152 | 2019 | — |
| 8 |
High Q Technologies
Developer of quantum-enabled electron paramagnetic resonance systems for protein analysis |
$10.2M | — | Seed | Seed Feb 2024 | 24 | 2013 | — |
| 9 |
Neurenati
Biotech company focused on developing therapies for rare diseases, with a current focus on Hirschsprung disease |
$2.9M | — | Seed | Seed Apr 2024 | — | 2020 | — |
| 10 |
CryoStasis
Developer of subzero unfrozen cell preservation platform for cell and gene therapy |
$8M | — | Seed | Seed Jul 2023 | 8 | 2022 | — |
| 11 |
Radient Technologies
Develops and markets high-value naturally derived plant extracts |
$2.6M | — | Public | Post IPO Apr 2023 | 50 | 2001 | — |
| 12 |
Liberum
Provider of protein synthesizers manufacturing, pre-clinical research, and drug development services among others |
$2M | — | Seed | Seed Jul 2023 | 3 | 2019 | — |
| 13 |
Therapure Biopharma
Contract development and manufacturing organization that specializes in the development, manufacture of complex biologics. |
$24.2M | — | Funding Raised | Conventional Debt Aug 2015 | 225 | 2008 | — |
| 14 |
Biomind Labs
Developer of novel pharmaceuticals targeting neurological disorders and related conditions |
$6M | — | Public | Post IPO Sep 2021 | 5 | 2005 | — |
| 15 |
Contract Pharmaceuticals
CDMO focused on manufacturing of semi-solid pharmaceutical drugs |
$9M | — | Acquired | Grant (prize money) May 2015 | 325 | 1991 | — |
| 16 |
CellCarta
CRO focused on providing histopathology and genomics services |
$7.5M | — | Acquired | Grant (prize money) Sep 2014 | 727 | 2002 | — |
| 17 |
Arthritis Research Canada
Company conducting and coordinating clinical trials for arthritis treatment |
$3M | — | Funding Raised | Grant (prize money) Sep 2014 | 68 | 2000 | — |
| 18 |
CEN Biotech
Holding company focused on hemp based healthcare services & products |
$2.6M | — | Seed | Conventional Debt Mar 2016 | 4 | 2013 | — |
| 19 |
Quality Green
Provider of medical cannabis |
$2M | — | Deadpooled | Seed Dec 2018 | 11 | 2015 | — |
| 20 |
PragmaClin
Provider of drug research & development services for neurological diseases |
$249K | — | Early Stage | Grant (prize money) Jun 2022 | 10 | 2020 | — |
| 21 |
Everest Clinical Research
Full service CRO offering clinical research services |
$75.3K | — | Acquired | Grant (prize money) Aug 2019 | 350 | 2004 | — |
| 22 |
Grey Wolf Animal Health
Provider of animal healthcare solutions |
$48.7K | — | Seed | Seed Mar 2019 | 19 | 2015 | — |
| 23 |
RNA Technologies and Therapeutics
Company focused on advancing the boundaries of medical science and revolutionizing healthcare through RNA-focused research and innovation |
— | — | Seed | Seed Feb 2024 | — | 2022 | — |
| 24 |
Proxima
Provider of contract research services for academic labs and life sciences, specializing in DNA vectors and protein reagents |
— | — | Seed | Seed Jan 2024 | — | 2021 | — |
| 25 |
Elkimia
Provides chemical intermediates for drug discovery |
— | — | Series A | Series A Aug 2022 | 8 | 2005 | — |
| 26 |
Advanced Electrophoresis Solutions
Provider of quality control and regulatory support services |
— | — | Seed | Seed Jun 2022 | 16 | 2010 | — |
| 27 |
CBS Bio Platforms
Provider of R&D and manufacturing services for products used in feed, food, industrial, and environmental applications |
— | — | Funding Raised | Unattributed Nov 2021 | — | 1984 | — |
| 28 |
48Hour Discovery
Developer of molecular discovery platform |
— | — | Funding Raised | Grant (prize money) 2020 | 19 | 2017 | — |
| 29 |
Nucro-Technics
Full-service bioanalytical CRO offering toxicity, bioanalytical and stability study services |
— | — | Acquired | Grant (prize money) Jul 2019 | 103 | 1970 | — |
| 30 |
BioVectra
Generic manufacturer and CDMO specializing in microbial fermentation |
— | — | Acquired | Grant (prize money) Mar 2019 | 600 | 1970 | — |
| 31 |
Nexelis
Provider of assay development and bioanalytical services |
— | — | Late Stage | PE 2018 | 299 | 1989 | — |
| 32 |
JSS Medical Research
Full-service CRO providing clinical trial management services in 21+ countries |
— | — | Acquired | Unattributed Oct 2014 | 200 | 1997 | — |
| 33 |
Dalton
Integrated drug discovery, development and manufacturing services |
— | — | Acquired | Grant (prize money) Mar 2013 | 146 | 1986 | — |
| 34 |
LMC Manna Research
One of the largest networks of outpatient clinical research centers in North America |
— | — | Late Stage | PE 2012 | 302 | 2005 | — |
| 35 |
35Pharma
Biopharmaceutical company manufacturing biologics products |
— | — | Acquired | — | 6 | 2021 | — |
| 36 |
a&c
A&C is a global GMP manufacturer of excipients, buffers, process solutions and a select number of active pharmaceutical ingredients (APIs). |
— | — | Acquired | — | 38 | 1966 | — |
| 37 |
Acanthus Research
Provider of data research services for biopharma sector |
— | — | Unfunded | — | 12 | 2008 | — |
| 38 |
Accelera Canada
Provider of advocacy, market access, and regulatory services for biopharma sector |
— | — | Acquired | — | 500 | 2017 | — |
| 39 |
AccelLAB
Provider of preclinical research services |
— | — | Acquired | — | 100 | 2004 | — |
| 40 |
Accucaps
Contract developer and manufacturer of softgel formulations |
— | — | Acquired | — | 500 | 1989 | — |
| 41 |
Acenzia
Developer of diagnostic and pharmaceutical products |
— | — | Acquired | — | 50 | 2015 | — |
| 42 |
AEquivalens
CRO offering project monitoring, site management and regional management services |
— | — | Unfunded | — | — | 2007 | — |
| 43 |
AffinityImmuno
Provides antibodies, custom antibodies and ELISA kits |
— | — | Unfunded | — | 3 | 2014 | — |
| 44 |
AGADA Biosciences
Drug development program expert specializing in neuromuscular diseases |
— | — | Funding Raised | — | 20 | 2013 | — |
| 45 |
Alcmaeon Pharma
Consulting services for clinical development |
— | — | Deadpooled | — | — | 2011 | — |
| 46 |
ALDA Pharmaceuticals
Provider of drug development & research and supply chain services for pharmaceutical industry |
— | — | Unfunded | — | — | 2003 | — |
| 47 |
Algorithme Pharma
Full-service early stage CRO offering its services in the US and Canada |
— | — | Acquired | — | 137 | 1992 | — |
| 48 |
Alimentiv
Provider of clinical developemnt services |
— | — | Unfunded | — | 583 | 1986 | — |
| 49 |
Allphase
A full-service contract research organization |
— | — | Acquired | — | — | 2001 | — |
| 50 |
Alphora Research
Company offering CDMO services for complex small molecules, including niche API’s, high potency and cytotoxic compounds. |
— | — | Acquired | — | 100 | 2003 | — |
Groupe LSL Pharma is a Canadian integrated pharmaceutical company that focuses on innovation in life science products to support the Canadian population. They have recently announced new orders with an annual revenue potential exceeding $2.6 million.
Digital pharmacotherapeutic platform for providers. It is a platform for the discovery and creation of natural chemicals with the potential for medicinal usage.
Developer of therapeutics for the treatment of skincare. The company is developing anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim to preserve and restore youthful skin and reverse aging.
CDMO focused on antibody discovery and pre-clinical services
Manufacturer of barium and iodine generic radiographic drugs
Provider of diversified CDMO services for radiotherapeutics
Provider of biopharma consulting services
Developer of quantum-enabled electron paramagnetic resonance systems for protein analysis. The company’s systems resolve complex problems in protein dynamics for drug discovery. It offers a sample measurement service to provide researchers with insights into molecular dynamics. The organization’s technology aims to redefine standards in protein structure determination.
Neurenati Therapeutics is a biotech company focused on developing therapies for rare diseases, with a current focus on Hirschsprung disease. The company recently concluded a $1.2 million seed financing round to advance the development of their NEU-001 therapy. CEO Maxime Ranger is a serial entrepreneur and venture capitalist in the life science space.
Developer of subzero unfrozen cell preservation platform for cell and gene therapy. The company’s platform uses media, temperature, and pressure to preserve biological material. The media formulation leverages cold shock inhibitors and membrane protectants. Temperature systems include devices and shipping solutions. Pressure systems lower the freezing point and cell metabolism, enabling long-term storage.
Radient Technologies operates in the business of extraction, purification and isolation compounds, and ingredients from plants for use in the production of pharmaceutical intermediates, nutraceuticals, foods, and cosmetic products. The products include valerenic acid, flax SDG, and carnosic acid. Radient produces these high-value natural substances by uniquely combining MAP (Microwave Assisted Processing), a patented
Developer of a biotechnology platform intended to democratize access to the fruits of synthetic biology. The company's platform uses proprietary molecular and hardware technology, protein synthesizers help to speed up the production of enzymes, therapeutics, and lab reagents, enabling clients to bring speed, scalability, and reduce cost.
FedDev Ontario
HHS
UTEST
3 Boomerang Capital
AQC Capital
AVAC Group
Afternic
Alberta Innovates
Ampersand Capital
Anges Quebec
Apollo Investment Corporation
Arsenal Capital Partners
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-19.
_1566992233167.png){kind=logo}
_1553066526982.png){kind=logo}
